Transforming Growth Factor‐β1 Suppresses Interleukin‐15‐Mediated Interferon‐γ Production in Human T Lymphocytes

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Scandinavian Journal of Immunology

• Publication date

  1999-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-3083.1999.00635.xPMID 10607309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-1 alpha (IL-1 alpha), IL-1 beta, IL-1 receptor type I, IL-1 receptor antagonist, and TGF-beta 1 mRNAs in pediatric astrocytomas, ependymomas, and primitive neuroectodermal tumors.

  1998cited by this paper
• Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy.

  1998cited by this paper
• Quantitative analysis of Th1, Th2 and TGF‐β1 cytokine expression in tumor, TIL and PBL of non‐small cell lung cancer patients

  1998cited by this paper
• Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-beta 1 expression.

  1998cited by this paper
• Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.

  1998cited by this paper
• Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.

  1998cited by this paper
• Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour‐infiltrating lymphocyte (TIL)‐derived T cell lines and established tumour cell lines

  1998cited by this paper
• Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes.

  1997cited by this paper
• Regulation of interleukin‐12 receptor β1 chain expression and interleukin‐12 binding by human peripheral blood mononuclear cells

  1997cited by this paper
• Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL‐10

  1997cited by this paper
• Demonstration of the Th1 to Th2 cytokine shift during the course of HIV‐1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry

  1997cited by this paper
• The role of interleukin-10 (IL-10) in IL-15-mediated T-cell responses.

  1997cited by this paper
• Differential regulation of human T lymphoblast functions by IL-2 and IL-15.

  1997cited by this paper
• Interleukin-15 protects from lethal apoptosis in vivo

  1997cited by this paper
• Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression.

  1997cited by this paper
• Interleukin‐15 up‐regulates interleukin‐2 receptor α chain but down‐regulates its own high‐affinity binding sites on human T and B cells

  1996cited by this paper
• Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas.

  1996cited by this paper
• Immunosuppressive cytokines (IL‐10, TGF‐β) genes expression in human gastric carcinoma tissues

  1996cited by this paper
• Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells

  1996cited by this paper
• TGF-beta 1 in colonic neoplasia. A genetic molecular and immunohistochemical study.

  1996cited by this paper
• Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumour bed.

  1996cited by this paper
• IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels.

  1996cited by this paper
• Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15.

  1996cited by this paper
• Identification and cloning of a novel IL‐15 binding protein that is structurally related to the alpha chain of the IL‐2 receptor.

  1995cited by this paper
• IL‐15, a novel T cell growth factor that shares activities and receptor components with IL‐2

  1995cited by this paper
• Characterization of B-cell lines established from two X-linked severe combined immunodeficiency patients: interleukin-15 binds to the B cells but is not internalized efficiently.

  1995cited by this paper
• Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state.

  1995cited by this paper
• Function of the interleukin-2 (IL-2) receptor gamma-chain in biologic responses of X-linked severe combined immunodeficient B cells to IL-2, IL-4, IL-13, and IL-15.

  1995cited by this paper
• Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.

  1995cited by this paper
• Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2.

  1995cited by this paper
• The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15.

  1995cited by this paper
• Transforming growth factor-beta-mediated regulation of human peripheral blood mononuclear cell proliferation as detected with phosphorothioate antisense oligodeoxynucleotides.

  1995cited by this paper
• Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines.

  1994cited by this paper
• Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumors.

  1994cited by this paper
• Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

  1994cited by this paper
• Transforming growth factor-beta inhibits IL-4 and IFN-gamma production by stimulated human T cells.

  1994cited by this paper
• Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

  1994cited by this paper
• Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15.

  1994cited by this paper
• Transforming Growth Factor‐β CD4+ T cells Tumor‐bearing state Immunosuppression Enhanced Production of TGF‐β and a Progressive Increase in TGF‐β Susceptibility of Anti‐tumor CD4+ T Cell Function

  1993cited by this paper
• Evidence that TGF-beta can inhibit human T-lymphocyte proliferation through paracrine and autocrine mechanisms.

  1993cited by this paper
• Effect of transforming growth factor-beta on early and late activation events in human T cells.

  1993cited by this paper
• Differential activation of CD8+ T cells by transforming growth factor-beta 1.

  1993cited by this paper
• Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.

  1992cited by this paper
• Transforming growth factor-beta inhibits human T-cell proliferation through multiple targets.

  1992cited by this paper
• Co-stimulation of T cell proliferation by transforming growth factor-beta 1.

  1991cited by this paper
• Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression.

  1990cited by this paper
• Transforming growth factors beta slow down cell‐cycle progression in a murine interleukin‐2 dependent T‐cell line

  1989cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

  1986cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper

• Regulatory mechanisms of transforming growth factor-β in senescence of fibroblast associated with refractory skin diseases.

  2025cites this paper
• Migration and homeostasis of regulatory T cells in rheumatoid arthritis

  2022cites this paper
• Secretion of immunoregulatory cytokines by mesenchymal stem cells.

  2014cites this paper
• Lower TGFß serum levels and higher frequency of IFNγ‐producing T cells during early immune reconstitution in surviving children after allogeneic stem cell transplantation

  2013cites this paper
• Extracts from Citrus unshiu promote immune-mediated inhibition of tumor growth in a murine renal cell carcinoma model.

  2011cites this paper
• Role of TGF-β and the tumor microenvironment during mammary tumorigenesis.

  2011cites this paper
• Transforming growth factor beta (TGF-beta) and inflammation in cancer.

  2010cites this paper
• Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.

  2008cites this paper
• TGF-β and Regulatory T Cell in Immunity and Autoimmunity

  2008cites this paper
• Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients.

  2008cites this paper
• TGF-Beta and Regulatory T Cells

  2008cites this paper
• Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy

  2007cites this paper
• ‘Yin–Yang’ functions of transforming growth factor‐β and T regulatory cells in immune regulation

  2007cites this paper
• Transforming growth factor-beta regulation of immune responses.

  2006cites this paper
• Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A.

  2006cites this paper
• Endogenous Transforming Growth Factor‐β Inhibits Toll‐Like Receptor Mediated Activation of Human Uterine Natural Killer Cells

  2006cites this paper
• Human NK cell IFN-gamma production is regulated by endogenous TGF-beta.

  2006cites this paper
• Assessing the Safety of Cytotoxic T Lymphocytes Transduced With a Dominant Negative Transforming Growth Factor-β Receptor

  2006cites this paper
• Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures

  2006cites this paper
• Human NK cell IFN-γ production is regulated by endogenous TGF-β

  2006cites this paper
• TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

  2005cites this paper
• Regulation of Interleukin‐2 Induced Soluble Fas Ligand Release from Human Peripheral Blood Mononuclear Cells

  2004cites this paper
• CHAPTER 18 – Interleukin-15 and 21

  2003cites this paper
• Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

  2002cites this paper
• Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

  2002cites this paper
• Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-β receptor type II

  2002cites this paper
• CO-OPERATION OF IL-1 AND IL-2 ON T-CELL ACTIVATION IN MONONUCLEAR CELL CULTURES

  2001cites this paper
• Suppression of IL-2-Induced T Cell Proliferation and Phosphorylation of STAT3 and STAT5 by Tumor-Derived TGFβ Is Reversed by IL-151

  2001cites this paper
• Reversed by IL-15 Is β and STAT 5 by Tumor-Derived TGF Proliferation and Phosphorylation of STAT 3 Suppression of IL-2-Induced T Cell

  2001cites this paper